Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13007862 | 0.96 | LYN (0.37) | PRKCA | |
| SCHEMBL13007866 | 0.92 | MAPK1 (0.36) | — | |
| SCHEMBL3782242 | 0.89 | ENPP2 (0.37) | — | |
| SCHEMBL3782223 | 0.89 | ENPP2 (0.37) | — | |
| SCHEMBL3768747 | 0.88 | — | — | |
| SCHEMBL13007864 | 0.84 | — | — | |
| SCHEMBL13007869 | 0.83 | ENPP2 (0.37) | — | |
| SCHEMBL13007859 | 0.83 | ENPP2 (0.37) | — | |
| SCHEMBL2997531 | 0.82 | CNR1 (0.38) | — | |
| SCHEMBL2999306 | 0.80 | ENPP2 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317624-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-12-16 | — | — | US | disclosed |
| US-20100317624-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-12-16 | — | — | US | disclosed |
| US-20100317624-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-12-16 | — | — | US | disclosed |
| WO-2010142978-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317624-A1 | HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF | UROD, UMPS, SLC14A1 | PRKCA 3379/4885PRKACB 745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.